Cancer Care Updates in the Era of COVID-19
Tuesday, July 21, 2020 at 07:00 PM Eastern Daylight Time.
Tuesday, July 21, 2020 at 07:00 PM Eastern Daylight Time.
The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety
Tara Schneider, PharmD, and her husband, Chuck Schneider, MBA, offer expanded clinical services in their Louisville, Kentucky, pharmacy.
The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.
Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.
Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, delve into the complexities of hepatic encephalopathy, exploring the various risk factors…
IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.
Each eight-week Private Practice Simple Solutions learning collaborative addresses one topic area important to private practices and begins with a webinar of pre-recorded content presented…
Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody that treats immune-mediated diseases such as psoriasis and psoriatic arthritis.
Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.
The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.